Kenvue Inc. (NYSE:KVUE) Shares Sold by D.A. Davidson & CO.

D.A. Davidson & CO. cut its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 30.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 108,872 shares of the company's stock after selling 48,375 shares during the quarter. D.A. Davidson & CO.'s holdings in Kenvue were worth $2,611,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in KVUE. Price T Rowe Associates Inc. MD increased its position in Kenvue by 3.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company's stock valued at $5,249,665,000 after buying an additional 8,211,748 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Kenvue by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company's stock valued at $4,665,908,000 after acquiring an additional 1,636,741 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Kenvue by 12.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock valued at $2,085,070,000 after purchasing an additional 10,682,003 shares during the last quarter. Geode Capital Management LLC boosted its stake in Kenvue by 3.1% in the 4th quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company's stock worth $980,989,000 after purchasing an additional 1,391,854 shares in the last quarter. Finally, Franklin Resources Inc. grew its position in Kenvue by 61.5% during the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock worth $912,059,000 after purchasing an additional 16,269,721 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on KVUE shares. Evercore ISI began coverage on Kenvue in a research report on Monday, March 24th. They issued an "in-line" rating and a $25.00 target price on the stock. Redburn Atlantic began coverage on Kenvue in a research report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 target price on the stock. Barclays raised their price target on shares of Kenvue from $22.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Monday, May 12th. UBS Group lifted their price objective on Kenvue from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Friday, May 9th. Finally, Citigroup reaffirmed a "neutral" rating on shares of Kenvue in a report on Friday, June 13th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $25.33.

Kenvue Price Performance

Shares of KVUE traded down $0.13 during trading hours on Monday, hitting $20.92. 11,615,630 shares of the stock were exchanged, compared to its average volume of 16,123,318. The stock's 50-day moving average price is $22.61 and its two-hundred day moving average price is $22.32. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 0.86. The company has a market cap of $40.14 billion, a price-to-earnings ratio of 38.04, a price-to-earnings-growth ratio of 3.27 and a beta of 0.83. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The firm had revenue of $3.74 billion for the quarter, compared to the consensus estimate of $3.69 billion. During the same quarter last year, the business posted $0.28 earnings per share. The firm's revenue was down 3.9% compared to the same quarter last year. Research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th were paid a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.92%. Kenvue's dividend payout ratio (DPR) is 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.